US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Anbio Biotechnology - Class A Ordinary Shares
(NQ:
NNNN
)
3.320
-0.330 (-9.04%)
Delayed Quote
Updated: 3:59 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Anbio Biotechnology - Class A Ordinary Shares
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
March 17, 2026
From
Anbio Biotechnology
Via
GlobeNewswire
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
August 08, 2025
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
From
Anbio Biotechnology
Via
GlobeNewswire
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
May 15, 2025
Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration
From
Anbio Biotechnology
Via
GlobeNewswire